Expression Of EGR4 And Its Clinical Significance In Epithelial Ovarian Cancer

Epithelial malignancy Ovarian is a common gynecological malignancy,but also the highest mortality rate of gynecological diseases.The main problems what face in clinical diagnosis and treatment of ovarian cancer are: Firstly,the early diagnosis of ovarian cancer difficult;secondly,epithelial ovarian cancer surgery without a net;thirdly,50%-70% of patients with epithelial ovarian cancer postoperative chemotherapy resistance.The current big problem on clinical is Lack of specific,efficiency of molecular targeted drugs treatment in epithelial ovarian cancer.So looking for the ovarian cancer-related genes is the key to solve the status quo for early diagnosis,therapeutic targets and prognosis of epithelial ovarian cancer.EGR4(NGFI-C)is a member of the immediate early gene(IEG)family,as a transcription factor,can regulate its upstream and downstream gene expression in the process of cell signaling.IEG family factor is known for its rapid response by external stimuli.When cells are stimulated by environmental factors such as growth factor,hormone,neurotransmitter,mitogen,ion,radiation,EGR is regulated by MAPK signal pathway and actives or inhibits of its downstream target gene expression,and play an irreplaceable role in transcriptional regulation.EGR1 has been researched in many tumors,which in different tissues has either pro-tumor effects or anti-tumor effects.In ovarian cancer tissue EGR1 has pro-tumor effect.Currently,EGR4 is applied to neural tissue and lung cancers widely.However,it is seldom used in other cancers.This study focus on the relationship between EGR4 and the drug resistance and prognosis in patients with epithelial ovarian cancer,then provide a theoretical basis for further research,clinical diagnosis and treatment of ovarian cancer.PurposesThis study aims to detect the expression of EGR4 in ovarian tumor tissue,to analyze the relationship between EGR4 and clinical factors of ovarian epithelial carcinoma,and to explore the correlation between EGR4 and drug resistance and prognosis of ovarian epithelial carcinoma.It is expected to predict the occurrence,development,tumor resistance and prognosis of ovarian epithelial carcinoma by the expression of EGR4.MethodsThis study has been approved by the Ethics Committee.1.Collected 86 cases of primary ovarian epithelial cancer patients with complete clinical data that were diagnosised in November 2006 to December 2012 in Xijing Hospital.Immunofluorescence assay were used to detect the expression of EGR4 protein in ovarian cancer,benign ovarian tumors and borderline ovarian tumors.Statistical method analyzes the relationship between the expression of EGR4 and the clinical index,drug resistance and prognosis.2.Collected 20 cases fresh specimens which were newly diagnosed as ovarian epithelial cancer in Obstetrics and Gynecology of Xijing Hospital.Fresh specimens of 10 cases of normal ovarian tissues and 10 cases of benign ovarian tissue,Western blot qualitative detection of EGR4 protein expression.3.Western blot was used to detect the expression of EGR4 protein in ovarian cancer cells A2780 and CP70.Results1.The expression of EGR4 was higher in ovarian epithelial carcinoma than that in ovarian epithelial benign tumor and ovarian epithelial borderline tumor tissues(p< 0.05);EGR4 protein was nuclear,pulp co-expression in ovarian cancer cells.2.The high expression rate of EGR4 was 60.5% in epithelial ovarian cancer tissue.The high expression rates of EGR4 were 37.5% and 74.1% of?-?period and ?-? period in epithelial ovarian cancer tissues,and the difference was statistically significant(p<0.05).The high expression rates of EGR4 in serous carcinoma,mucinous carcinoma and other epithelial ovarian cancer were 68.7%,27.3% and 20.0% respectively,the expression of EGR4 was statistically significant(p <0.05);The high expression rate of EGR4 with lymph node metastais was 70.0%,while the high expression rate of EGR4 without lymph node metastasis was 36.9%,they were statistically significant(p <0.05).The high expression rates of EGR4 in patients with ascites and without ascites were 68.3% and 44.0%,and they had a significant difference(p <0.05).The high expression rates of EGR4 in patients with satisfactory or unsatisfactory cytoreductve surgery were 50% and 76.5%,and the difference was statistically significant(p <0.05).But the expression of EGR4 in histological differentiation and tumor size were not statistically significant(p> 0.05).3.The expression of EGR4 in ovarian epithelial carcinoma was not correlated with platinum resistance in patients(p> 0.05),4.There was no significant correlation between the expression of EGR4 and the survival time of ovarian epithelial carcinoma(p> 0.05).Conclusion1.EGR4 is highly expressed in ovarian epithelial cancer,which may play an important role in the development and progression of ovarian epithelial cancer.EGR4 is expressed in ovarian cancer cells.EGR4 protein was expressed in nuclear,pulp co-expression of ovarian cancer cells.2.The expression of EGR4 in ovarian epithelial carcinoma was correlated with FIGO staging,pathological type,lymph node metastasis,ascites and cytoreductve surgery(p <0.05),but no correlation with histological differentiation and tumor size(p> 0.05).3.The expression of EGR4 in ovarian epithelial carcinoma was not correlated with platinum resistance in patients(p> 0.05),4.EGR4 expression is not a main factor affecting the prognosis of ovarian epithelial cancer patients and EGR4 was not the specific biomolecule of patients with ovarian cancer.